HGH Fragment 176-191 vs CagriSema
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Frag 176-191, HGH Frag
The lipolytic fragment of human growth hormone. Contains the fat-burning portion of HGH without effects on blood sugar or cell proliferation.
Also: Semaglutide + Cagrilintide
A combination of semaglutide and cagrilintide (amylin analog). The most effective weight loss drug candidate, showing 22.7% body weight reduction in Phase 3 trials - superior to any single-agent GLP-1.
Key Comparison Insights
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
Detailed Comparison
| Attribute | HGH Fragment 176-191 | CagriSema |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Fragment 176-191 mimics the way natural HGH regulates fat metabolism but without adverse effects on blood sugar or growth. It stimulates lipolysis and inhibits lipogenesis, specifically targeting adipose tissue. | Combines GLP-1 receptor agonism (semaglutide) with amylin receptor agonism (cagrilintide). Amylin adds satiety signaling and slows gastric emptying through different pathways than GLP-1. |
| Common Dosing | 250-500 mcg daily 1-2x daily, fasted | Limited community data available See research protocols |
| Administration | Subcutaneous injection on empty stomach | Subcutaneous injection weekly |
| Typical Duration | 8-12 weeks | Long-term use expected |
| Best Time to Take | Before bed or morning (fasted) | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Studies show enhanced fat loss, particularly in abdominal area. Research demonstrates no impact on glucose metabolism or IGF-1 levels. Works synergistically with diet and exercise for body composition improvement. | Phase 3 REDEFINE 1 trial showed 22.7% weight loss at 68 weeks, significantly outperforming semaglutide alone (15.8%). NDA submitted to FDA in December 2025. If approved, expected to become the leading obesity treatment. |
Frequently Asked Questions: HGH Fragment 176-191 vs CagriSema
What is the difference between HGH Fragment 176-191 and CagriSema?
HGH Fragment 176-191 is a weight loss peptide that the lipolytic fragment of human growth hormone. contains the fat-burning portion of hgh without effects on blood sugar or cell proliferation. CagriSema is a weight loss peptide that a combination of semaglutide and cagrilintide (amylin analog). the most effective weight loss drug candidate, showing 22.7% body weight reduction in phase 3 trials - superior to any single-agent glp-1. The main differences lie in their mechanisms of action and clinical applications.
Which is better, HGH Fragment 176-191 or CagriSema?
Neither is universally "better" - the choice depends on your specific goals. HGH Fragment 176-191 is typically used for weight loss purposes, while CagriSema is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can HGH Fragment 176-191 and CagriSema be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using HGH Fragment 176-191 and CagriSema together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of HGH Fragment 176-191 and CagriSema is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.